{
    "clinical_study": {
        "@rank": "122770", 
        "acronym": "AGCRC-013", 
        "arm_group": [
            {
                "arm_group_label": "Andrographolides with Capecitabine", 
                "arm_group_type": "Experimental", 
                "description": "Capecitabine1250mg/m2 , bid\uff0cd1-14\uff0cq3w, Andrographolides 500mg\uff0cqd\uff0cd1-14\uff0cq3w;"
            }, 
            {
                "arm_group_label": "Capecitabin alone", 
                "arm_group_type": "Active Comparator", 
                "description": "Capecitabine1250mg/m2 , bid\uff0cd1-14\uff0cq3w,"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine the efficacy and safety of Andrographolides\n      combined with Capecitabine in treatment of elderly patients with locally advanced or\n      recurrent or metastasis inoperable colorectal cancer"
        }, 
        "brief_title": "Study of Andrographolides With or Without Capecitabine to Treat Colorectal Cancer", 
        "completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Colorectal Neoplasms", 
        "condition_browse": {
            "mesh_term": [
                "Neoplasms", 
                "Colorectal Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Histologically or cytologically confirmed diagnosis of adenocarcinoma of the colon or\n             rectum\n\n          2. Locally advanced or recurrent or metastasis inoperable disease\n\n          3. At least 1 measurable or non-measurable lesion per RECIST version 1.1 guidelines.\n             Lesion must not be chosen from a previously irradiated field unless there had been\n             documented tumor progression in that lesion prior to randomization. All sites of\n             disease must be evaluated \u2264 28 days prior to randomization.\n\n          4. Man or woman \u2265 65 years of age\n\n          5. Hematological function, as follow: (\u2264 10 days prior to randomization)\n\n               -  Absolute neutrophil count (ANC) \u2265 1.5\u00d7109/L\n\n               -  Platelet count \u2265 75\u00d7109/L\n\n               -  Hemoglobin \u2265 8.0 g/dL\n\n          6. Renal function, as follows: (\u2264 10 days prior to randomization)\n\n               -  Creatinine\u2264 1.5\u00d7ULN\n\n          7. Hepatic function, as follow: (\u2264 10 days prior to randomization)\n\n               -  Aspartate aminotransferase (AST) \u2264 3\u00d7ULN(if liver metastases\u2264 5\u00d7ULN )\n\n               -  Alanine aminotransferase (ALT) \u2264 3\u00d7ULN(if liver metastases\u2264 5\u00d7ULN )\n\n               -  Total bilirubin\u2264 1.5\u00d7ULN\n\n          8. Subject or subject's legally acceptable representative has provided informed consent\n\n        Exclusion Criteria:\n\n          1. Symptomatic brain metastases requiring treatment\n\n          2. History of other malignancy, except:\n\n               -  Malignancy treated with curative intent and with no known active disease present\n                  for \u2265 5 years prior to randomization and felt to be at low risk for recurrence\n                  by the treating physician\n\n               -  Adequately treated non-melanomatous skin cancer or lentigo maligna without\n                  evidence of disease\n\n               -  Adequately treated cervical carcinoma in situ without evidence of disease\n\n               -  Prostatic intraepithelial  neoplasia without evidence of prostate cancer\n\n          3. Antitumor therapy(eg, chemotherapy, hormonal therapy, immunotherapy, antibody\n             therapy) \u2264  21 days before randomization. Subjects must have recovered from any acute\n             radiotherapy-related toxicity\n\n          4. Radiotherapy\u2264 14 days before randomization. Subjects must have recovered from any\n             acute radiotherapy-related toxicities\n\n          5. Clinically significant cardiovascular disease (including myocardial infarction,\n             unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac\n             arrhythmia)\u2264 6 months prior to randomization\n\n          6. History of interstitial lung disease(ILD) eg, interstitial pneumonitis, pulmonary\n             fibrosis or evidence of ILD on baseline chest CT or MRI\n\n          7. History of any medical or psychiatric condition or labortory abnomality that in the\n             opinion of the investigator may increase the risk associated with the study\n             participation or investigational product administration or may interfere with the\n             interpretation of the results\n\n          8. Unstable pulmonary embolism, deep vein thrombosis, or other significant\n             arterial/venous thromboembolic event \u2264 30 days before randomization. If on\n             anticoagulation, subject must be on stable therapeutic dose prior to rangdomization.\n\n          9. Subject has any kind of disorder that compromises the ability of the subject to give\n             written informed consent and/or to comply with study procedures or is unwilling or\n             unable to comply with study requirements"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "65 Years"
        }, 
        "enrollment": {
            "#text": "308", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 12, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01993472", 
            "org_study_id": "AGCRC-013", 
            "secondary_id": "ANDRO-JSPPH-2013"
        }, 
        "intervention": [
            {
                "arm_group_label": "Andrographolides with Capecitabine", 
                "description": "comparison of efficacy of Andrographolides combined with Capecitabine or Capecitabine alone in treatment of colorectal cancer", 
                "intervention_name": "Andrographolides", 
                "intervention_type": "Drug", 
                "other_name": "xiyanpingzhusheye"
            }, 
            {
                "arm_group_label": [
                    "Andrographolides with Capecitabine", 
                    "Capecitabin alone"
                ], 
                "intervention_name": "Capecitabine", 
                "intervention_type": "Drug", 
                "other_name": "Xeloda"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Andrographolide", 
                "Capecitabine", 
                "Fluorouracil"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "November 20, 2013", 
        "location": {
            "contact": {
                "email": "oncotar@163.com", 
                "last_name": "Yanhong Gu, Ph.D", 
                "phone": "13813908678"
            }, 
            "facility": {
                "address": {
                    "city": "Nanjing", 
                    "country": "China", 
                    "state": "Jiangsu", 
                    "zip": "210029"
                }, 
                "name": "the First Affiliated Hospital of Nanjing Medical University"
            }, 
            "investigator": [
                {
                    "last_name": "Yanhong Gu, Ph.D", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Yongqian Shu, Ph.D", 
                    "role": "Principal Investigator"
                }
            ], 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "Andrographolides With or Without Capecitabine for Elderly Patients With Locally Advanced or Recurrent or Metastasis Inoperable Colorectal Cancer: a Randomized, Open-label Trial.", 
        "overall_contact": {
            "email": "oncotar@163.com", 
            "last_name": "Yanhong Gu, Ph.D", 
            "phone": "008613813908678"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "China: Ethics Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Progression free survival (PFS)", 
            "safety_issue": "No", 
            "time_frame": "From  date  of  randomization  until  the  date  of  first  documented progression\uff0cassessed  up to  100  months"
        }, 
        "reference": {
            "PMID": "23202296", 
            "citation": "Bruchard M, Mignot G, Derang\u00e8re V, Chalmin F, Chevriaux A, V\u00e9gran F, Boireau W, Simon B, Ryffel B, Connat JL, Kanellopoulos J, Martin F, R\u00e9b\u00e9 C, Apetoh L, Ghiringhelli F. Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth. Nat Med. 2013 Jan;19(1):57-64. doi: 10.1038/nm.2999. Epub 2012 Dec 2."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01993472"
        }, 
        "responsible_party": {
            "investigator_affiliation": "The First Hospital of Nanjing Medical University", 
            "investigator_full_name": "Gu Yanhong", 
            "investigator_title": "Director", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "overall survival", 
                "safety_issue": "Yes", 
                "time_frame": "From  date  of  randomization  until  the  date of death  from  any cause\uff0cassessed  up to  100  months"
            }, 
            {
                "measure": "Response Rate", 
                "safety_issue": "No", 
                "time_frame": "From  date  of  randomization  until  the  date  of  first  documented partial response or complete response, assessed  up to  100  months"
            }, 
            {
                "measure": "Quality of Life", 
                "safety_issue": "Yes", 
                "time_frame": "From  date  of  randomization  until  the  date of death  from  any cause\uff0cassessed  up to  100  months"
            }
        ], 
        "source": "The First Hospital of Nanjing Medical University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Gu Yanhong", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}